Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 3.88
ALRPRB's Operating margin (%) is ranked higher than
75% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ALRPRB: 3.88 )
ALRPRB' s 10-Year Operating margin (%) Range
Min: 0   Max: 0
Current: 3.88

Net-margin (%) -4.60
ALRPRB's Net-margin (%) is ranked higher than
66% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ALRPRB: -4.60 )
ALRPRB' s 10-Year Net-margin (%) Range
Min: 0   Max: 0
Current: -4.6

ROE (%) -9.05
ALRPRB's ROE (%) is ranked higher than
65% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ALRPRB: -9.05 )
ALRPRB' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -9.05

ROA (%) -1.94
ALRPRB's ROA (%) is ranked higher than
67% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. ALRPRB: -1.94 )
ALRPRB' s 10-Year ROA (%) Range
Min: 0   Max: 0
Current: -1.94

» ALRPRB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ALRPRB Guru Trades in Q1 2013

Howard Marks 185,800 sh (New)
Pioneer Investments 127,839 sh (unchged)
Private Capital 5,232 sh (-7.68%)
» More
Q2 2013

ALRPRB Guru Trades in Q2 2013

Howard Marks 190,800 sh (+2.69%)
Private Capital 5,362 sh (+2.48%)
Pioneer Investments 127,839 sh (unchged)
» More
Q3 2013

ALRPRB Guru Trades in Q3 2013

Howard Marks 207,800 sh (+8.91%)
Pioneer Investments 127,839 sh (unchged)
Private Capital 5,342 sh (-0.37%)
» More
Q4 2013

ALRPRB Guru Trades in Q4 2013

Howard Marks 212,800 sh (+2.41%)
Private Capital 5,342 sh (unchged)
Pioneer Investments 127,839 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.424.03

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.03
ALRPRB's Dividend Yield is ranked lower than
228% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.28 vs. ALRPRB: 4.03 )
ALRPRB' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 4.03

Yield on cost (5-Year) 4.04
ALRPRB's Yield on cost (5-Year) is ranked lower than
84% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ALRPRB: 4.04 )
ALRPRB' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 4.04

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:IM5.Germany
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take charge of improving their health and quality of life at home by developing new capabilities in near-patient diagnosis, monitoring and health management. The Company's global products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. The Company's main reportable operating segments are professional diagnostics, health management and consumer diagnostics. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals and doctors' offices and, increasingly, testing and monitoring done at home at the direction of the medical professional, or through patient self-testing. Professional diagnostic products provide for qualitative or quantitative analysis of a patient's body fluids or tissue for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The Company's health management business strives to empower participants of its programs and physicians so they could work together towards better health. It also provides services supporting home INR testing. Its health management business is principally conducted in the United States. The Company's other current consumer diagnostic products consist of its market-leading First Check brand of over-the-counter drugs of abuse tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for alcohol abuse, cholesterol monitoring and colon cancer screening. The Company's manufacturing facilities are located in San Diego, California; Scarborough, Maine; Dundee, Scotland; Oslo, Norway; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. It also manufactures products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. Its competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. The main competitors for its professional rapid diagnostic products are Becton Dickinson, Quidel and Meridian Bioscience.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide